NCT06385990招募中2 期
Clinical Study of the Efficacy and Safety of Utidelone (UTD1) Combined With Capecitabine as Adjuvant Therapy in Non-pCR Triple-negative Breast Cancer Patients After Neoadjuvant Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 53
- 试验地点
- 1
- 主要终点
- 2-year disease-free survival (DFS)
研究概览
简要总结
This trial is a multicenter, single-arm clinical trial to evaluate the efficacy and safety of UTD1 in combination with capecitabine for the adjuvant treatment of TNBC patients who did not achieve pathologic complete remission after neoadjuvant therapy. TNBC patients who did not achieve pathological complete remission or positive lymph node after neoadjuvant chemotherapy received adjuvant treatment with study drug.
Solution: UTD1 30mg / m², once a day on days 1-5; capecitabine: 1000mg / m², days 1-14, oral, twice / day; 21 days a treatment cycle of 6-8 cycles.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent;
- •18 Years and older;
- •Breast cancer confirmed by pathological histology, ER-negative (<1% positive), PR-negative (<1% positive), and HER2-negative (IHC: HER2 (0), HER2 (1+), or HER2 (2+) and FISH non-amplification;
- •Patients must receive full course of neoadjuvant chemotherapy before surgery and did not achieve pathological complete response (i. e., pathologically confirmed residual lesion, maximum diameter of 1cm) or / lymph node positive (ypN+);
- •Previous neoadjuvant chemotherapy regimen included anthracycline, taxane, or a combination of both.
- •Patients who clinically require radiotherapy of the affected breast or chest wall and regional lymph node area should receive radiotherapy before or after study medication;
- •All toxicities related to previous antitumor therapy must return to Grade 1 (CTCAE v5.0), except alopecia;
- •Within 1 week before enrollment, the blood routine examination was basically normal (taking the normal value of each study center as the standard): 1) Blood routine: hemoglobin (Hb) > 90g / L, White blood cell count (WBC) > 3.5*10^9 / L, Number of neutrophils (ANC) * 1.5*10^9 / L, Platelet count (PLT)* 100*10^9 / L; 2) Renal function: upper limit of normal serum creatinine value; 3) Liver function: for patients without liver metastasis: glutamulate aminotransferase (AST), glutamate aminotransferase (ALT), alkaline phosphatase (ALP) are less than 2.5 times of the upper limit of normal value, and totle bilirubin is less than 1.25 times of the upper limit of normal value; for patients with liver metastasis, AST, ALT, ALP, ALT, ALP, are less than 5 times of the upper limit of normal value, and totle bilirubin is less than 1.25 times of the upper limit of normal value;
- •The ECOG physical status score for patients must be 0 or 1;
排除标准
- •Metastatic breast cancer at diagnosis;
- •Breast cancer patients who did not completed surgery;
- •History of other malignancies within 5 years prior to randomization, but patients with the following tumors may participate in the study: carcinoma of the cervix in situ, colon in situ, melanoma in situ and basal cell carcinoma of the skin and squamous cell carcinoma;
- •Any other non-malignant systemic disease (cardiovascular, renal, liver, etc.) that hinders the implementation or follow-up of the treatment program;
- •Symptomatic congestive heart failure (New York Heart Association Grade II-IV), symptomatic or poorly controlled arrhythmia, history of congenital long QT syndrome or corrected QTc> 500ms at screening, history of uncontrolled hypertension or hypertensive crisis or hypertensive encephalopathy;
- •History of interstitial pneumonia, Need for steroids or evidence of active pneumonia;
- •Suffering from an active autoimmune disease, and required systemic treatment in the past 2 years (i. e., use of disease regulators, corticosteroids, or immunosuppressive drugs);
- •Patients with a known infection with human immunodeficiency virus (HIV);
- •Patients with active infections requiring systemic treatment;
- •Any hormonal medication (such as raloxifene, tamoxifen, or other selective oestrogen receptor modulators) for osteoporosis or breast cancer prophylaxis (only patients who have discontinued these drugs before randomization may participate in the study);
- •The patient received either capecitabine or utiderone before surgery;
- •Pregnant or lactating women;
- •Known or suspected allergy to any study drug or excipients;
- •Prohibition of corticosteroids;
- •Any other condition the investigator considers inappropriate to participate in the trial.
研究组 & 干预措施
UTD1 in combination with capecitabine
Experimental
UTD1 30mg / m², once a day on days 1-5; capecitabine: 1000mg / m², days 1-14, oral, twice / day; 21 days a treatment cycle of 6-8 cycles.
干预措施: UTD1 (Drug)
结局指标
主要结局
2-year disease-free survival (DFS)
时间窗: 2 years
2-year DFS will be defined as the percentage of patients alive without recurrence or metastasis of disease at 2 years measured from the date of enrollment.
次要结局
- Overall Survival (OS)(Up to 2 years (from date of enrollment to the date of death).)
- Distant Disease-free Survival (DDFS)(From the date of surgery to distant recurrence, or death due to any cause (up to 2 years).)
- Disease Free Survival (DFS)(Up to 2 years (from date of surgery to the date of recurrence / metastasis).)
- Invasive Disease free survival (iDFS)(From the date of surgery to the time of invasive local, axillary or distant recurrence, invasive contralateral breast cancer or death from any cause (whichever occurs first)., up to 2 years.)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal CancerEsophageal CancerNCT05866510Peking University47
招募中
2 期
The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical StudyTNBC - Triple-Negative Breast CancerNCT06125080Huihua Xiong78
招募中
2 期
Utidelone Injection Combined With Gemcitabine in First-line Chemotherapy for Unresectable Advanced Pancreatic CancerPancreatic NeoplasmsNCT05795920Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine92
终止
不适用
Peri-orbital and Peri-oral Wrinkle Reduction TrialPeri-orbital WrinklesPeri-oral WrinklesNCT01981252Ulthera, Inc90
招募中
2 期
Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)Newly Diagnosed Peripheral T-cell LymphomaNCT05976997Liling Zhang36